BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Glaxo  Group  Limited  submitted  on  21  July  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Avamys,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 28 April 2006. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain tests or 
studies. 
The applicant applied for the following indications 
Adults / Adolescents (12 years and over) 
Treatment of the symptoms of seasonal allergic rhinitis: 
In patients with seasonal allergic rhinitis, fluticasone furoate nasal spray is effective for the 
treatment of nasal symptoms (rhinorrhoea, nasal congestion, nasal itching and sneezing) and 
ocular symptoms (itching/burning, tearing/watering, and redness of the eye).  
Treatment of the symptoms of perennial allergic rhinitis: 
In patients with perennial allergic rhinitis, fluticasone furoate nasal spray is effective for the 
treatment of nasal symptoms (rhinorrhoea, nasal congestion, nasal itching and sneezing). 
Children (2 to 11 years) 
Treatment of the symptoms of seasonal allergic rhinitis: 
In patients with seasonal allergic rhinitis, fluticasone furoate nasal spray is effective for the 
treatment of nasal symptoms (rhinorrhoea, nasal congestion, nasal itching and sneezing). 
Treatment of the symptoms of perennial allergic rhinitis: 
In patients with perennial allergic rhinitis, fluticasone furoate nasal spray is effective for the 
treatment of nasal symptoms (rhinorrhoea, nasal congestion, nasal itching and sneezing). 
Following the CHMP assessment the following indication was granted: 
Adults, adolescents (12 years and over) and children (6-11 years) 
Avamys is indicated for the treatment of: 
the symptoms of allergic rhinitis 
• 
Scientific Advice 
The applicant received Scientific Advice from the CHMP on 30 July 2004. The Scientific Advice 
pertained to clinical aspects of the dossier. 
Licensing status 
At the time of submission a new application was filed in the following countries: U.S.A. 
The product was not licensed in any country at the time of submission of the application. 
©EMEA 2008 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Michal Pirozynski (PL) 
Co-Rapporteur:  David Lyons (IRL) 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 21 July 2006. 
The procedure started on 16 August 2006. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 5 November 
2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 31 
October 2006. 
During  the  meeting  on  11-14  December  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 14 December 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  16 
March 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 26 April 2007. 
During  the  CHMP  meeting  on  21  –  24  May  2007, the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and in an oral explanation by the applicant. 
The  summary  report  of  the  inspection  carried  out  at  the  following  site:  Huntingdon  Research 
Centre, Woolley Road, Alconbury, Cambridgeshire UK on 6-7 June 2007 was issued on 23 July 
2007. 
The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on 
03 August 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 26 August 2007, and an updated Overview on 
11 September 2007. 
During the CHMP meeting on 17-20 September 2007, outstanding issues were addressed by the 
applicant during an oral explanation before the CHMP. 
The  applicant  submitted  a  clarification,  draft  SPC  and  draft  letter  of  undertaking  on  25 
September 2007. 
The Rapporteurs circulated the Joint Assessment on the clarification to all CHMP members on 
11 October 2007. 
During  the  meeting  on  15-18  October  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Avamys on 18 October 2007. The applicant provided the 
letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 16 October 
2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 11 January 2008. 
©EMEA 2008 
2/2 
 
 
 
